- Home
- ALXO vs GDTC Comparison
ALXO vs GDTC Comparison
Compare ALXO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- GDTC
- Stock Information
- Founded
- ALXO 2015
- GDTC 2018
- Country
- ALXO United States
- GDTC Singapore
- Employees
- ALXO N/A
- GDTC N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- GDTC Health Care
- Exchange
- ALXO Nasdaq
- GDTC Nasdaq
- Market Cap
- ALXO 24.0M
- GDTC 28.0M
- IPO Year
- ALXO 2020
- GDTC 2023
- Fundamental
- Price
- ALXO $0.48
- GDTC $2.28
- Analyst Decision
- ALXO Strong Buy
- GDTC Buy
- Analyst Count
- ALXO 6
- GDTC 1
- Target Price
- ALXO $3.30
- GDTC $5.00
- AVG Volume (30 Days)
- ALXO 397.6K
- GDTC 10.1K
- Earning Date
- ALXO 08-07-2025
- GDTC 01-01-0001
- Dividend Yield
- ALXO N/A
- GDTC N/A
- EPS Growth
- ALXO N/A
- GDTC N/A
- EPS
- ALXO N/A
- GDTC N/A
- Revenue
- ALXO N/A
- GDTC $368,838.00
- Revenue This Year
- ALXO N/A
- GDTC $5.37
- Revenue Next Year
- ALXO N/A
- GDTC N/A
- P/E Ratio
- ALXO N/A
- GDTC N/A
- Revenue Growth
- ALXO N/A
- GDTC N/A
- 52 Week Low
- ALXO $0.41
- GDTC $1.20
- 52 Week High
- ALXO $8.78
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- ALXO 44.63
- GDTC 57.60
- Support Level
- ALXO $0.48
- GDTC $2.04
- Resistance Level
- ALXO $0.59
- GDTC $2.14
- Average True Range (ATR)
- ALXO 0.05
- GDTC 0.06
- MACD
- ALXO -0.00
- GDTC 0.02
- Stochastic Oscillator
- ALXO 8.75
- GDTC 91.67
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.